A phase 2 study of niraparib concomitant with tumor treating fields in patients with recurrent grade 4 glioma
Neuro-Oncology Advances · 12.01.2026 · 8 (1)
DOI: 10.1093/noajnl/vdag076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 20.04.2026. Verfasst von Elizabeth C Cordell und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline and Novocure.
Abstract (Originalsprache)
Background
In preclinical models, tumor treating fields (TTFields) therapy promotes homologous repair deficiency (HRD), inducing potential sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition. The aim of this study was to determine whether TTFields combined with the brain-penetrant PARP inhibitor niraparib has clinical efficacy in patients with recurrent high-grade glioma (HGG).
Methods
We conducted a phase 2 trial of TTFields therapy concomitant with niraparib in patients with glioblastoma (n = 7) or IDH-mutant grade 4 astrocytoma (n = 2) that was recurrent after prior radiotherapy. Cohort A was a single-arm primary efficacy cohort with the Simon’s 2-stage design. Cohort B was a surgical window-of-opportunity cohort in which TTFields were administered for 5-7 days prior to surgery and then resumed post-operatively with niraparib. The primary endpoint was disease control rate in cohort A, defined as objective response or stable disease (SD) lasting at least 16 weeks.
Results
The most common treatment-related adverse events were grade 1-2 dermatologic (scalp) toxicity in 67% of patients and grade 1-2 nausea in 67% of patients. In cohort A (n = 8), there were no objective responses, and 1 patient (12.5%) achieved SD lasting over 16 weeks. The efficacy benchmark to advance to Stage 2 was not achieved, and enrollment on Cohort A was terminated for futility. Cohort B (n = 1) was closed early due to slow accrual. In the single patient in Cohort B, TTFields-treated tumor tissue was negative for HRD.
Conclusions
The combination of niraparib and TTFields therapy for recurrent HGG was safe and well tolerated but did not demonstrate an efficacy signal.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Elizabeth C Cordell, Ali Nabavizadeh, Suyash Mohan, E Paul Wileyto, Steven Brem, Stephen J Bagley
Förderung
- GlaxoSmithKline and Novocure
Zitieren
APA
Cordell, E. C., Mansour, M., Pantel, A. R., Schubert, E., Nabavizadeh, A., Mohan, S., Maloney, E., Prior, T., Angeloni, N., Blessing, C., Frangos, S., Coghlan, L., Wileyto, E. P., O'Rourke, D. M., Brem, S., Desai, A. S., & Bagley, S. J. (2026). A phase 2 study of niraparib concomitant with tumor treating fields in patients with recurrent grade 4 glioma. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag076
Vancouver
Cordell EC, Mansour M, Pantel AR, Schubert E, Nabavizadeh A, Mohan S, et al. A phase 2 study of niraparib concomitant with tumor treating fields in patients with recurrent grade 4 glioma. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag076
BibTeX
@article{Cordell2026,
author = {Cordell, Elizabeth C and Mansour, Maikel and Pantel, Austin R and Schubert, Erin and Nabavizadeh, Ali and Mohan, Suyash and Maloney, Eileen and Prior, Timothy and Angeloni, Natalie and Blessing, Caroline and Frangos, Suzanne and Coghlan, Leah and Wileyto, E Paul and O'Rourke, Donald M and Brem, Steven and Desai, Arati S and Bagley, Stephen J},
title = {A phase 2 study of niraparib concomitant with tumor treating fields in patients with recurrent grade 4 glioma},
journal = {Neuro-Oncology Advances},
year = {2026},
volume = {8},
number = {1},
doi = {10.1093/noajnl/vdag076}
}
EUVIMED